D
Douglas D. Richman
Researcher at University of California, San Diego
Publications - 637
Citations - 85518
Douglas D. Richman is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Virus & Viral load. The author has an hindex of 142, co-authored 633 publications receiving 82806 citations. Previous affiliations of Douglas D. Richman include Monogram Biosciences & University of California, Davis.
Papers
More filters
Journal ArticleDOI
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial.
Margaret A. Fischl,Douglas D. Richman,M. H. Grieco,M. S. Gottlieb,Paul A. Volberding,Oscar L. Laskin,John M. Leedom,Jerome E. Groopman,Donna Mildvan,Robert T. Schooley +9 more
TL;DR: It is demonstrated that AZT administration can decrease mortality and the frequency of opportunistic infections in a selected group of subjects with AIDS or AIDS-related complex, at least over the 8 to 24 weeks of observation in this study.
Journal ArticleDOI
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
Diana Finzi,Monika Hermankova,Theodore C. Pierson,Lucy M. Carruth,Christopher B. Buck,Richard E. Chaisson,Thomas C. Quinn,Karen Chadwick,Joseph B. Margolick,Ron Brookmeyer,Joel E. Gallant,Martin Markowitz,David D. Ho,Douglas D. Richman,Robert F. Siliciano +14 more
TL;DR: In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4+ T lymphocytes, and generally did not show mutations associated with resistance to the relevant antiretroviral drugs.
Journal ArticleDOI
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.
Joseph K. Wong,Marjan Hezareh,Huldrych F. Günthard,Diane V. Havlir,Caroline Ignacio,Celsa A. Spina,Douglas D. Richman +6 more
TL;DR: In this article, the authors showed that activation of patient CD4 lymphocytes with immobilized antibodies to CD3 and CD28 enabled the isolation of virus from six patients despite the suppression of their plasma HIV RNA to fewer than 50 copies per milliliter for up to 2 years.
Update of the Drug Resistance Mutations in HIV-1.
Victoria A. Johnson,F. Brun-Vezinet,Bonaventura Clotet,Huldrych F. Günthard,Daniel R. Kuritzkes,Deenan Pillay,Jonathan M. Schapiro,Douglas D. Richman +7 more
TL;DR: The International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group reviews new data on HIV-1 drug resistance that have been published or presented at recent scientific meetings to maintain a current list of mutations associated with antiretroviral drug resistance.
Journal ArticleDOI
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
Roy M. Gulick,John W. Mellors,Diane V. Havlir,Joseph J. Eron,Charles J. Gonzalez,Deborah McMahon,Douglas D. Richman,Fred T. Valentine,Leslie Jonas,Anne R. Meibohm,Emilio A. Emini,Chodakewitz Jeffrey A +11 more
TL;DR: In most HIV-infected patients with prior antiretroviral therapy, the combination of indinavir, zidovudine, and lamivudine reduces levels of HIV RNA to less than 500 copies per milliliter for as long as one year.